کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10964396 | 1102712 | 2014 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium
ترجمه فارسی عنوان
هزینه مقرون به صرفه واکسیناسیون فصلی آنفولانزا در زنان باردار، کارکنان بهداشتی و افراد مبتلا به بیماری های زمینه ای در بلژیک
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
سرماخوردگی واکسیناسیون، گروه های خطر، هزینه یابی، بارداری، ایمن مسن،
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
چکیده انگلیسی
Risk groups with increased vulnerability for influenza complications such as pregnant women, persons with underlying illnesses as well as persons who come into contact with them, such as health care workers, are currently given priority (along with other classic target groups) to receive seasonal influenza vaccination in Belgium. We aimed to evaluate this policy from a health care payer perspective by cost-effectiveness analysis in the three specific target groups above, while accounting for effects beyond the target group. Increasing the coverage of influenza vaccination is likely to be cost-effective for pregnant women (median â¬6589 per quality-adjusted life-year (QALY) gained [â¬4073-â¬10,249]) and health care workers (median â¬24,096/QALY gained [â¬16,442-â¬36,342]), if this can be achieved without incurring additional administration costs. Assuming an additional physician's consult is charged to administer each additional vaccine dose, the cost-effectiveness of vaccinating pregnant women depends strongly on the extent of its impact on the neonate's health. For health care workers, the assumed number of preventable secondary infections has a strong influence on the cost-effectiveness. Vaccinating people with underlying illnesses is likely highly cost-effective above 50 years of age and borderline cost-effective for younger persons, depending on relative life expectancy and vaccine efficacy in this risk group compared to the general population. The case-fatality ratios of the target group, of the secondary affected groups and vaccine efficacy are key sources of uncertainty.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 32, Issue 46, 21 October 2014, Pages 6075-6083
Journal: Vaccine - Volume 32, Issue 46, 21 October 2014, Pages 6075-6083
نویسندگان
Adriaan Blommaert, Joke Bilcke, Yannick Vandendijck, Germaine Hanquet, Niel Hens, Philippe Beutels,